Unexpected findings show that the body’s own immune system destroys retinal cells.
Glaucoma, a disease that afflicts nearly 70 million people worldwide, is something of a mystery despite its prevalence. Little is known about the origins of the disease, which damages the retina and optic nerve and can lead to blindness.
A new study from MIT and Massachusetts Eye and Ear has found that glaucoma may in fact be an autoimmune disorder. In a study of mice, the researchers showed that the body’s own T cells are responsible for the progressive retinal degeneration seen in glaucoma. Furthermore, these T cells appear to be primed to attack retinal neurons as the result of previous interactions with bacteria that normally live in our body.
The discovery suggests that it could be possible to develop new treatments for glaucoma by blocking this autoimmune activity, the researchers say.
“This opens a new approach to prevent and treat glaucoma,” says Jianzhu Chen, an MIT professor of biology, a member of MIT’s Koch Institute for Integrative Cancer Research, and one of the senior authors of the study, which appears in Nature Communications on Aug. 10.
Dong Feng Chen, an associate professor of ophthalmology at Harvard Medical School and the Schepens Eye Research Institute of Massachusetts Eye and Ear, is also a senior author of the study. The paper’s lead authors are Massachusetts Eye and Ear researchers Huihui Chen, Kin-Sang Cho, and T.H. Khanh Vu.
Genesis of glaucoma
One of the biggest risk factors for glaucoma is elevated pressure in the eye, which often occurs as people age and the ducts that allow fluid to drain from the eye become blocked. The disease often goes undetected at first; patients may not realize they have the disease until half of their retinal ganglion cells have been lost.
Most treatments focus on lowering pressure in the eye (also known as intraocular pressure). However, in many patients, the disease worsens even after intraocular pressure returns to normal. In studies in mice, Dong Feng Chen found the same effect.
“That led us to the thought that this pressure change must be triggering something progressive, and the first thing that came to mind is that it has to be an immune response,” she says.
To test that hypothesis, the researchers looked for immune cells in the retinas of these mice and found that indeed, T cells were there. This is unusual because T cells are normally blocked from entering the retina, by a tight layer of cells called the blood-retina barrier, to suppress inflammation of the eye. The researchers found that when intraocular pressure goes up, T cells are somehow able to get through this barrier and into the retina.
The Mass Eye and Ear team then enlisted Jianzhu Chen, an immunologist, to further investigate what role these T cells might be playing in glaucoma. The researchers generated high intraocular pressure in mice that lack T cells and found that while this pressure induced only a small amount of damage to the retina, the disease did not progress any further after eye pressure returned to normal.
Further studies revealed that the glaucoma-linked T cells target proteins called heat shock proteins, which help cells respond to stress or injury. Normally, T cells should not target proteins produced by the host, but the researchers suspected that these T cells had been previously exposed to bacterial heat shock proteins. Because heat shock proteins from different species are very similar, the resulting T cells can cross-react with mouse and human heat shock proteins.
To test this hypothesis, the team brought in James Fox, a professor in MIT’s Department of Biological Engineering and Division of Comparative Medicine, whose team maintains mice with no bacteria. The researchers found that when they tried to induce glaucoma in these germ-free mice, the mice did not develop the disease.
The researchers then turned to human patients with glaucoma and found that these patients had five times the normal level of T cells specific to heat shock proteins, suggesting that the same phenomenon may also contribute to the disease in humans. The researchers’ studies thus far suggest that the effect is not specific to a particular strain of bacteria; rather, exposure to a combination of bacteria can generate T cells that target heat shock proteins.
One question the researchers plan to study further is whether other components of the immune system may be involved in the autoimmune process that gives rise to glaucoma. They are also investigating the possibility that this phenomenon may underlie other neurodegenerative disorders, and looking for ways to treat such disorders by blocking the autoimmune response.
“What we learn from the eye can be applied to the brain diseases, and may eventually help develop new methods of treatment and diagnosis,” Dong Feng Chen says.
The Latest on: Glaucoma
via Google News
The Latest on: Glaucoma
Staying fit might cut glaucoma risk
on August 17, 2018 at 11:09 am
(Reuters Health) - Meeting physical activity guidelines and being physically fit may reduce the risk of developing glaucoma by 40 percent to 50 percent, recent research suggests. Among nearly 10,000 p... […]
Less-invasive options are slowing disease progression in glaucoma patients
on August 17, 2018 at 10:36 am
Judith Smith, now 71, was at a routine appointment several years ago with her longtime ophthalmologist when the doctor made a comment that her right eye looked a little suspicious for glaucoma, an inc... […]
New Understanding of Glaucoma
on August 17, 2018 at 8:25 am
Immune cells in the eye that developed in response to early exposure to bacteria are a key contributor to progressive vision loss from glaucoma, the second leading cause of irreversible blindness in t... […]
Glaucoma Surgery Devices Market Estimated to Expand at a Robust CAGR by 2026
on August 17, 2018 at 2:24 am
Albany, NY -- (SBWIRE) -- 08/17/2018 -- Glaucoma is an ocular disease which affects the optic nerve of the iris and progression of the same results in vision loss and blindness. According to the World ... […]
Local doctor participating in glaucoma prevention trial, hopes to make history
on August 16, 2018 at 3:45 pm
DAYTON, Ohio (WDTN) - A local eye doctor is taking part in an FDA trial that aims to slow down the effects of glaucoma. Two of the three trial procedures done in the U.S. were done right here in Dayto... […]
Aerie confirms Rhopressa’s mechanism of action in open-angle glaucoma, ocular hypertension
on August 15, 2018 at 7:45 am
Aerie Pharmaceuticals confirmed the effect of Rhopressa on trabecular meshwork outflow in patients with open-angle glaucoma or ocular hypertension, according to the topline results of a double-masked, ... […]
FDA Clears Hydrus Microstent for Glaucoma
on August 14, 2018 at 4:46 pm
The US Food and Drug Administration (FDA) has approved the Hydrus (Ivantis) microstent to treat mild-to-moderate, primary open-angle glaucoma in conjunction with cataract surgery. Roughly the size of ... […]
MIT research points to autoimmune disease as the cause of glaucoma
on August 12, 2018 at 6:48 pm
The body's own immune cells may be the culprit behind the slow retinal deterioration associated with glaucoma(Credit: MIT) An exciting breakthrough from a team of researchers MIT and Massachusetts Eye ... […]
Study: Glaucoma may be autoimmune disorder
on August 11, 2018 at 12:32 pm
SATURDAY, Aug. 11, 2018 -- The eye disease glaucoma may be an autoimmune disorder, a new study suggests. Glaucoma affects nearly 70 million people worldwide. It damages the retina and optic nerve and ... […]
via Bing News